Neurocrine Biosciences (NASDAQ:NBIX) Given New $169.00 Price Target at Barclays

Neurocrine Biosciences (NASDAQ:NBIX) had its target price upped by Barclays from $150.00 to $169.00 in a research report report published on Thursday, Benzinga reports. They currently have an overweight rating on the stock.

NBIX has been the subject of a number of other research reports. Wells Fargo & Company upgraded shares of Neurocrine Biosciences from an equal weight rating to an overweight rating and upped their price objective for the stock from $140.00 to $170.00 in a research report on Wednesday, April 24th. The Goldman Sachs Group increased their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a buy rating in a report on Thursday, January 25th. Oppenheimer lifted their price objective on Neurocrine Biosciences from $200.00 to $216.00 and gave the company an outperform rating in a report on Thursday. Needham & Company LLC reissued a hold rating on shares of Neurocrine Biosciences in a research note on Wednesday. Finally, HC Wainwright lifted their price target on Neurocrine Biosciences from $150.00 to $160.00 and gave the company a buy rating in a research note on Thursday. Six research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $147.88.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX traded up $0.88 during trading on Thursday, hitting $140.71. 616,567 shares of the company were exchanged, compared to its average volume of 795,508. The firm’s 50 day moving average price is $137.37 and its 200-day moving average price is $128.78. The stock has a market capitalization of $14.16 billion, a P/E ratio of 38.76 and a beta of 0.28. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The company had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. During the same period last year, the firm earned $0.88 EPS. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. As a group, equities research analysts anticipate that Neurocrine Biosciences will post 4.79 EPS for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider David W. Boyer sold 456 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the completion of the transaction, the insider now directly owns 4,894 shares of the company’s stock, valued at $694,752.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Neurocrine Biosciences news, insider David W. Boyer sold 456 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total transaction of $64,733.76. Following the sale, the insider now directly owns 4,894 shares of the company’s stock, valued at approximately $694,752.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ingrid Delaet sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at approximately $1,088,965.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 181,547 shares of company stock worth $25,039,887. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds have recently made changes to their positions in NBIX. Mather Group LLC. purchased a new position in Neurocrine Biosciences during the first quarter worth about $26,000. Headinvest LLC purchased a new position in shares of Neurocrine Biosciences during the 3rd quarter worth about $28,000. Lindbrook Capital LLC lifted its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after acquiring an additional 96 shares during the period. EdgeRock Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter worth approximately $31,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.